Part I Introduction.- 1. Global strategy for influenza viral infection: What is the latest Information from WHO?.- Part II Definition, Epidemiology, and Pathogenesis.- 2. Epidemiology of influenza with a description of recent trends in Japan: What are the key epidemiologic features of seasonal influenza in terms of time, place, person, and virus (overall and in Japan)?.- 3. Transmission of influenza virus in the home: How are they transmitted in the home?.- 4. Cellular and biochemical pathogenic processes in severe influenza virus infection: How does cytokine storm plays a role?.- 5. Pathology of severe influenza virus pneumonia: what is the importance of alveolar mouths?.- 6. Pathology, Diagnosis, and Treatment of Influenza Infections/Pneumonia: What are the mechanisms of secondary bacterial pneumonia?.- Part III Diagnosis.- 7. Rapid diagnosis of influenza viral infection: What are the rapid diagnostic tests and molecular diagnosis?.- 8. Differential diagnosis between influenza and other respiratory viral infections: What are the differential diagnoses?.- 9. Radiologic findings of influenza pneumonia: What are the recent radiological findings?.- 10. Oral findings of influenza viral infection: What are the characteristic pharyngeal findings of influenza?.- Part IV Complication.- 11. Classification of pneumonia complicated with influenza viral infection: What are the patterns of pneumonia?.- 12. Influenza encephalopathy: What is encephalopathy?.- Part V Management.- 13. Treatment guidelines for influenza virus infection: What does the recent guideline state?.- 14. Treatment strategy for influenza viral infection in adolescent: what is the current adolescent treatment?.- 15. How to use anti-influenza drugs: zanamivir and oseltamivir.- 16. How to use anti-influenza drugs: laninamivir octanoate.- 17. How to use anti-influenza drugs: baloxavir marboxil.- 18. How to use anti-influenza drugs: peramivir.- 19. Prophylaxis of influenza viral transmission: What is the current prophylaxis?.- Part VI Topics.- 20. Influenza vaccine efficacy/effectiveness: with special reference to current epidemiological methodology.- 21. The new anti-influenza drug baloxavir marboxil: Can influenza viruses with reduced susceptibility to baloxavir maintain viral fitness?.- 22. Viruses resistant to oseltamivir or baloxavir: What do the data reveal about resistance?.
This book explores the latest research and practical data on the clinical management of influenza. Starting with the definition, epidemiology and pathogenesis, the first part reviews the basic science of the influenza virus and infection. The next three parts then discusses the diagnosis, complications and management, providing practical data and insights that are useful in day-to-day patient care. The last part focuses on the trending topics, including a new drug, oral baloxavir marboxil, which was introduced in Japan in 2018 and is the first polymerase inhibitor to be licensed for the treatment of uncomplicated influenza. In Japan, since the medical insurance system is well-established, patients receive medical examinations quickly after the onset of influenza viral infection, making it easy to implement early diagnostic tools and early treatment. Providing practical data and insights, Influenza - Advances in Diagnosis and Management is a useful resource for clinicians, residents and trainees around the globe.
Prof. Jiro Fujita
Department of Infectious, Respiratory, and Digestive Medicine, Control and Prevention of Infectious Diseases, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan